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600 KAUSTIO ET ALBackground: Homozygous loss of DIAPH1 results in seizures,
cortical blindness, and microcephaly syndrome (SCBMS). We
studied 5 Finnish and 2 Omani patients with loss of DIAPH1
presenting with SCBMS, mitochondrial dysfunction, and
immunodeficiency.
Objective: We sought to further characterize phenotypes and
disease mechanisms associated with loss of DIAPH1.
Methods: Exome sequencing, genotyping and haplotype
analysis, B- and T-cell phenotyping, in vitro lymphocyte
stimulation assays, analyses of mitochondrial function,
immunofluorescence staining for cytoskeletal proteins and
mitochondria, and CRISPR-Cas9 DIAPH1 knockout in heathy
donor PBMCs were used.
Results: Genetic analyses found all Finnish patients homozygous
for a rare DIAPH1 splice-variant (NM_005219:c.68411G>A)
enriched in the Finnish population, and Omani patients
homozygous for a previously described pathogenic DIAPH1
frameshift-variant (NM_005219:c.2769delT;p.F923fs). In
addition to microcephaly, epilepsy, and cortical blindness
characteristic to SCBMS, the patients presented with infection
susceptibility due to defective lymphocyte maturation and 3
patients developed B-cell lymphoma. Patients’
immunophenotype was characterized by poor lymphocyte
activation and proliferation, defective B-cell maturation, and
lack of naive T cells. CRISPR-Cas9 knockout of DIAPH1 in
PBMCs from healthy donors replicated the T-cell activation
defect. Patient-derived peripheral blood T cells exhibited
impaired adhesion and inefficient microtubule-organizing
center repositioning to the immunologic synapse. The clinical
symptoms and laboratory tests also suggested mitochondrial
dysfunction. Experiments with immortalized, patient-derived
fibroblasts indicated that DIAPH1 affects the amount of
complex IV of the mitochondrial respiratory chain.
Conclusions: Our data demonstrate that individuals with
SCBMS can have combined immune deficiency and implicate
defective cytoskeletal organization and mitochondrial
dysfunction in SCBMS pathogenesis. (J Allergy Clin Immunol
2021;148:599-611.)
Key words: DIAPH1, SCBMS, microcephaly, mitochondrial
dysfunction, T cells, immunodeficiency
DIAPH1 encodes for the evolutionarily conserved formin
diaphanous homolog 1 (DIAPH1 or mDIA1), which acts
downstream of Rho GTPases promoting F-actin polymerization
and microtubule stabilization.1-3 DIAPH1 is composed of an
N-terminal regulatory GTPase-binding-diaphanous inhibitory
domain followed by a dimerization domain, 2 highly conserved
formin homology domains (FH1 and FH2) that orchestrate actin*These authors contributed equally to this study.
This work was supported by the Academy of Finland, Finland (decision nos. RH: 317711,
266498, 273790), Ester and Uuno Kokki Foundation, Finland; the Finnish Cultural
Foundation, Finland; The Foundation for Pediatric Research, Finland; the Alma and
KA Snellman Foundation, Finland; and Special State Grants for Health Research at
the Oulu University Hospital, Finland (grant no. VTR K56772).
Disclosure of potential conflict of interest: The authors declare that they have no relevant
conflicts of interest.
Received for publication June 22, 2020; revised November 15, 2020; accepted for publi-
cation December 8, 2020.polymerization, and a C-terminal diaphanous autoregulatory
domain.4,5 Cytoskeletal dynamics are relevant for many cellular
processes, and hence formins have been implicated in cell
morphology, differentiation, adhesion, migration, and prolifera-
tion in several cell types.5 DIAPH1 also participates in regulating
mitochondrial trafficking by inducing docking of the
mitochondria to the cytoskeleton.6,7 DIAPH1 has also been
implicated in several steps of brain development, including neural
migration and neurite formation.8
DIAPH1 knockout mice present with ventricular enlargement
(brain atrophy) at early and postnatal stages and have marked
defects in the function of several types of immune cells.9-14
DIAPH1 is the predominant isoform of the 3 diaphanous-
related proteins (DIAPH1-DIAPH3) in T cells and regulates
T-cell function through effects on microtubule-organizing center
(MTOC) polarization and actin accumulation at the immunologic
synapse.9,14,15 As a result, DIAPH12/2 mice develop
lymphopenia and show defective adherence, migration,
chemotaxis, and proliferation of T cells.9,14 In addition, the aging
DIAPH12/2 mice spontaneously develop a myeloproliferative
phenotype.16
In humans, DIAPH1 has been implicated in both cancer17,18
and heritable monogenic disease: Dominant gain-of-function
variants in DIAPH1 cause sensorineural deafness with
macrothrombocytopenia (DFNA1),19-21 whereas homozygous
loss of DIAPH1 causes seizures, cortical blindness, and
microcephaly syndrome (SCBMS). In SCBMS, the seizures
typically start during the first 6 months of life and are difficult
to manage. Head size can be normal at birth, but progressive
microcephaly, cortical blindness, and severe intellectual
disability soon become evident. Patients can also have difficulty
to thrive and have reduced height and weight. In previous studies,
some patients suffered bronchiectasis or recurrent respiratory
infections, but no clear immunodeficiency or cause for these
symptoms was shown.12,22
Until now, the SCBMS syndrome has been reported in only 3
consanguineous families, with a total of 9 patients homozygous
for damaging DIAPH1 variants (NM_005219: c.2332C>T;
p.Q778X, c.2769delT;p.F923fs, c.3145C>T;p.R1049X).12,22Available online March 1, 2021.
Corresponding author: Janna Saarela, MD, PhD, POBox 20, FI-00014, University of Hel-
sinki, Finland. E-mail: janna.saarela@helsinki.fi.
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KAUSTIO ET AL 601Here, we report 5 Finnish patients homozygous for a previously
unpublished pathogenic DIAPH1 splice-donor variant
(c.68411G>A), as well as 2 additional Omani patients homozy-
gous for the previously described p.F923fs variant. In addition,
we extend the clinical and molecular phenotype of SCBMS by
showing that patients with SCBMS can present with combined
immunodeficiency, lymphoma, and mitochondrial dysfunction,
and provide evidence for the role of DIAPH1 in the function of
mitochondria and the human immune system.METHODS
Sequencing and genomic analyses
DNA and RNA extraction, whole-exome sequencing (WES) and capillary
sequencing, genotyping, and data analysis are described in this article’s
Methods section in the Online Repository at www.jacionline.org.
Primers are listed in Table E1 in this article’s Online Repository at
www.jacionline.org.Cell isolation and culture
Fibroblast cultures were established from skin biopsies at the Department
of Clinical Genetics of Oulu University Central Hospital. Fibroblasts were
immortalized by a retroviral vector that expresses the E7 gene of type 16
human papilloma virus and a retroviral vector that expresses the protein
component of human telomerase.23 PBMCs were isolated from heparin blood
using Ficoll-Paque PLUS (GEhealthcare, Chicago, Ill) gradient centrifuga-
tion. Peripheral blood lymphocytes (PBLs) were collected after 3- to 16-
hour monocyte attachment to culture flasks. Culture media are listed in this ar-
ticle’s Methods section in the Online Repository.Cloning and lentiviral transduction
Full-length human wild-type (WT)-DIAPH1 cDNA was amplified from
control fibroblasts by RT-PCR and ligated into a Gateway-compatible
pLXSH-puro lentiviral vector (Invitrogen/ThermoFisher, Waltham Mass).
Forty-eight hours after transfection of a Phoenix packaging cell line,
lentivirus-containing medium was collected and used in mixture with 4 mg/
mL polybrene to transduce fibroblasts as described elsewhere.24Immunophenotyping
Clinical immunophenotyping and T-cell receptor-repertoire analyses were
performed by the laboratories of Oulu University Hospital, Helsinki
University Hospital, Turku University Hospital, and the Royal Hospital and
Sultan Qaboos University Hospital Oman. Phenotyping of IL-17–positive
TH17 cells and regulatory T cells is described in detail elsewhere.
25
TH1/TH17-cell cytokine measurements are described in this article’s
Methods section in the Online Repository. Neutrophil oxidative burst was
analyzed with dihydrorhodamine test.Lymphocyte proliferation assays
Lymphocyte proliferation was measured with 3H-thymidine incorporation
(as described elsewhere26), EDU incorporation according to manufacturer’s
recommendations (Invitrogen Click-iT-EdU), or by imaging-based estimation
of cell confluence and cell counting (see this article’s Methods section in the
Online Repository). PBMCs/PBLs were stimulated in the presence of 10 to 20
ng/ml IL-2 (Peprotech, Rocky Hill, NJ) in RPMI media with 10% FBS. Stim-
ulations were performed with PHA (Sigma-Aldrich, St Louis, Mo), concanav-
alin A, pokeweed mitogens, 1:1 or 1:2 cell-bead ratio of Gibco Dynabeads
Human T-Activator CD3/CD28 beads (ThermoFisher, Waltham, Mass), or 1
mg/mL soluble anti-CD3 (OKT3) and anti-CD28 (CD28.2) (Invitrogen) for
a maximum of 3 days, after which culture was continued in media with IL-2.Activation marker analysis
Cells were stimulated as described above, and expression of
activation markers analyzed by flow cytometry after 16 to 48 hours.
Combinations of the following antibodies were used: BV605-CD3
(#563217), BV421-CD4 (#562425), PE-Cy7-CD8 (#335822),
BV786-CD69 (#563834), and PE-CF594-CD25 (#562525) (all from
BD Biosciences, Franklin Lakes, NJ) and BV570-CD8 (#301038;
BioLegend, San Diego, Calif). DRAQ7 (BD Biosciences) and eFluor
660 (ThermoFisher) were used to gate out dead cells. For DIAPH1
staining, samples were fixed and permeabilized in methanol for 30
minutes, washed, stained for 60 minutes at room temperature for
surface markers and rabbit monoclonal DIAPH1 antibody (1:200;
ab129167; Abcam, Cambridge, UK), washed, and stained with
AF488 goat antirabbit secondary antibody (1:10000; #A11008; Invi-
trogen). Samples were run on the iQue Screener PLUS flow cytometer
and analyzed with ForeCyt software (Sartorius, Goettingen, Germany).PAGE and western blotting
Blots were probed by the following primary antibodies: SDHA #ab14715,
UQCRC2 #ab14745, COX IV #ab14744, ATP5A #ab14748, and DIAPH1
#ab129167 (Abcam); NDUFA9 #A21344 (Life Technologies/ThermoFisher,
Waltham, Mass); and GAPDH #258 (ThermoFisher). Secondary detection
was performed with Goat Anti-Mouse IgG HRP #1031-05 (SouthernBiotech,
Birmingham, Ala), Goat Anti-Rabbit IgG H&L #ab97080 (Abcam) or Swine
Anti-rabbit Ig/HRP #P0399 (Dako/Agilent, Santa Clara, Calif), and ECL
reagents (Pierce, Appleton, Wis). Total protein was detected with No-stain
Protein Labeling Reagent (Invitrogen/ThermoFisher). Imaging was
performed with the ChemiDoc MP Imaging System (Bio-Rad, Hercules,
Calif), and relative intensity of bandswas calculated using Image J software or
ImageLab 6.0 (Bio-Rad). Blottingmethods are described in more detail in this
article’s Methods section in the Online Repository.Immunocytochemistry
Detailed methods for immunofluorescence stainings are described in
this article’s Methods section in the Online Repository. Briefly, 1- or
10-day cultured T cells were plated on ICAM-1 and CD3 antibody or
CD3/CD28 antibody–coated surface, let attach for 1 hour, and fixed
with 2% or 4% formaldehyde in PBS. Cells were stained with
either (a) Mitotracker Deep Red (#M22426; ThermoFisher; staining of
live cells before fixation) or AF647 Phalloidin (#A22287; Invitrogen)
and AF555-conjugated a-Tubulin antibody (#MA1-38000-A555;
ThermoFisher) and Hoechst 33342 (#14533; Sigma-Aldrich) or (b) Cyto-
Painter Phalloidin iFluor 488 Reagent (#ab176753; Abcam) and Hoechst.
Cells were imaged with Olympus FluoView FV1000 confocal microscope
or PerkinElmer Opera Phenix high-content confocal microscope at 603
or 633, respectively. Identical exposure time and offsetting was used
for all samples. Images were exported and further analyzed with Harmony
4.9 software in 3D or Fiji.27 Parameters are listed in Table E2 in this
article’s Online Repository at www.jacionline.org.
CRISPR-Cas9 knockout of DIAPH1 in healthy donor
PBMCs
DIAPH1Alt-RCRISPR-Cas9 crRNAguides (listed in Table E1; IDT) were
combined 1:1 with Alt-R CRISPR-Cas9 tracrRNA (IDT, 1072533), annealed
at 958C for 5 minutes, and cooled to room temperature. RNPs were produced
by complexing 2 DIAPH1 guides (guide 1 1 2 or guide 1 1 3, each at 100
pmol/sample) with Alt-R S.p. Cas9 Nuclease V3 (IDT; 1081059; 100 pmol)
and incubated at room temperature for 15 minutes. Healthy donor PBMCs
were stimulated in complete RPMI media with ImmunoCult Human
CD3/CD28 T Cell Activator (STEMCELL Technologies, Vancouver, British
Columbia, Canada) and 3 ng/mL IL-7 and IL-15 (Peprotech) for 3 days. Cells
were resuspended at 1 million cells/20 mL 1 mol electroporation buffer and
electroporated using Lonza 4D Nucleofector X unit (Lonza, AAF-1002X),
electroporation program ‘‘EO-115,’’ and ‘‘Primary-Cell-P3’’ solution. After
TABLE I. Summary of phenotypic characteristics of the studied patients
Characteristic
Patient
F1.P1 F1.P2 F2.P3 F3.P4 F4.P5 F5.P6 F5.P7
Age (y) — 7 3 — 3
Age of
death (y)
9 6 — — 29 3 —
Sex Male Male Male Female Female Female Male
Cause of
death




22.5 SD at 1.5 y
to 25.5 SD)
Progressive (from
21.0 SD at birth
to 25.5 SD)
Progressive (from
23.7 SD at birth
to 27.6 SD at 4
y 5 mo)
Progressive (from
21.4 SD at birth
to 26.3 SD at 2
y 1 mo)
Progressive Progressive (from
22.0 SD at 10
wk to 24.8 SD
at 3 y 2 mo)
Progressive (from
fourth percentile
at 3 wk to 24.5





















Normal at the age
of 5 d
Occipital atrophy
at age 27 y,
encephalitis at
age 29 y





Profound Profound Profound Profound Profound Profound Profound
Epilepsy
onset
2 mo 2 mo 2.5 mo 2 d 1 mo 2 mo 15 d
Visual
impairment















































































CMV, Cytomegalovirus; HSV, herpes simplex virus; JCV, John Cunningham virus; MRSA, methicillin-resistant Staphylococcus aureus; RSV, respiratory syncytial virus;
VZV, varicella-zoster virus.
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602 KAUSTIO ET ALelectroporation, 80 mL/sample of RPMI with 10% FBS and IL-2 at 500 U/mL
was added and cells were allowed to rest at 378C for 15 minutes, followed by
transfer into 24-well plate in 400 mL medium. Cells were since cultured at a
concentration of 0.5 to 2 3 106/mL. Five days after electroporation, cells
were restimulated either as before electroporation or with 1:2 ratio of CD3/
CD28 beads (ThermoFisher). After 16 and 40 hours, cells were collected
for activation marker analysis by flow cytometry.Statistics and data visualization
Welch t test (fluorescence intensity) and Student t test (western blot band
intensities, imaging data) were used to calculate P values between groups.
Data were handled and plotted with R (4.0.3) using the ggplot2 package in
Rstudio (v1.3.1093).28,29Study approval
This study was approved by the Regional Ethics Committee of the
Northern Ostrobothnia and the Research and Ethics Review and Approval
Committee in Ministry of Health, Oman, and conducted according to the
principles of the Helsinki Declaration. Written informed consents were
obtained from caregivers of the patients, their family members, and healthy
controls.RESULTS
Identification of patients with DIAPH1-related
disease
We studied 7 patients with SCBMS originating from Finland
and Oman, who presented with a global developmental delay with
progressive microcephaly, drug-resistant early-onset epileptic
seizures, cortical blindness, and deficiency of cellular immunity
(Table I). To identify a genetic cause for the disease, we acquired
WES of all patients. WES data were analyzed for rare
(frequency <0.01), exonic or splice region variants that followed
either X-chromosomal–recessive, autosomal-recessive,
or compound heterozygous inheritance, as well as for de novo
variants. WES identified a homozygous splice-donor variant
in DIAPH1 (chr5:140961878, C>T; rs766545876; NM_
005219:c.68411G>A) in all Finnish patients, although the
families were not known to share recent ancestry. The variant
was validated by targeted capillary sequencing (see Fig E1 in
this article’s Online Repository at www.jacionline.org). In the 2
Omani patients, diagnostic WES analyses found a homozygous,
previously published pathogenic NM_005219:














































































1.4 1.8 3.1 5.3 0.6 3.0 3.2 5.1


















































































































1 400 600 800 1000 1272200
B
FIG 1. Genetics and effects of DIAPH1 variants. A, Pedigrees of studied families. For F1, only those siblings
who participated in segregation analysis are displayed. B, DIAPH1 protein structure showing published
SCBMS-causing variants. Variants found in patients in this article are marked in red. C, Gel separation of
PCR amplicons spanning the variant from patient-derived and parental cDNA. D, Total protein from patient
and healthy control–derived fibroblasts or PBMCs was run on SDS-PAGE gel, blotted, and probed for
DIAPH1. GAPDHwas used as a loading control. E, Total protein from PBL of 2 healthy controls was collected
every 2 days since stimulation (stim) by anti-CD3/CD28, blotted, and probed for DIAPH1. Numbers below
bands indicate relative band volume intensity after total protein normalization, with the average of the
0-day samples set to 1. Black line indicates samples were run on the same gel but were noncontiguous.
F, Lengths of shared haplotype segments around the c.68411G>A variant in phased array data. Data
from patients (GSA-chip) are shown as dark gray bars, and data from heterozygous carriers (PCC1-20,
CoreExome-chip) are shown as light gray bars. Numbers next to bars represent haplotype arm lengths
around the variant (black vertical line) in megabases (Mb).G,MDS plot (first 2 dimensions) was constructed
to visualize genetic distances between 20 variant carriers in a Finnish population cohort. Gray dots:
noncarrier, yellow dots: DIAPH1 c.68411G>A heterozygote.GAPDH, Glyceraldehyde-3-phosphate dehydro-
genase; HC, healthy control; MAT, maternal haplotype; MDS, multidimensional scaling; PAT, paternal
haplotype.
J ALLERGY CLIN IMMUNOL
VOLUME 148, NUMBER 2
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filtering in families 1, 4, and 5 are listed in Table E3 in this arti-
cle’s Online Repository at www.jacionline.org.
Analysis of patient-derived cDNA showed that the
c.68411G>A variant resulted in aberrant splicing of DIAPH1
(Fig 1, C; see Fig E2 and capillary sequencing results in this
article’s Online Repository at www.jacionline.org). Only WT
transcript was detected in heterozygotes, possibly due to dosagecompensation and preferential PCR amplification of the more
abundant WT transcript. Western blot of immortalized fibroblast
and PBMC total protein extracts indicated total loss of the
DIAPH1 protein in patients (Fig 1, D). In control fibroblasts,
only the 141-kDa full-length DIAPH1 was detected, whereas
unstimulated control PBMCs contained very little of the
full-length protein and higher amounts of a shorter isoform of
approximately 75 kDa.15 In healthy donor PBMCs in response
TABLE II. Immunophenotype of patients with SCBMS
Parameter
Patient
Reference valuesF1.P1 F1.P2 F2.P3 F3.P4 F4.P5 F5.P6 F5.P7
Age at sampling (y) 9 4 7 3 25 3 3
Leukocytes 8.0 11.0 9.5 13.4 6.0 NA NA 4.5-13.5 3 109
Neutrophils 4.8 4.1 6.2 7.1 4.8 0.7 Y 2.6 4.5-13.5 3 109
Lymphocytes 2.1 5.1 1.4 4.6 1.0 Y 0.48 Y 4.6 1.2-3.5 3 109
CD191 B cells 437 765 342 1597 312 1% Y 760 a: 80-616 / 17%-26%
Transitional CD38hiIgMhi NA NA 11.1% [ 19.1% [ 6.3%[ LowY 11% [ a: 0.6%-3.5%
Naive CD272IgD1IgM1 NA NA 89.8% [ 94.6% 72.2% LowY 82% a: 43.2%-82.4%
Memory CD271 NA NA 8.2%Y 4.4%Y 1.5%Y LowY 5%Y
Marginal zone
CD271IgD1IgM1
NA NA 4.2% Y 2.2% Y 0.5% Y LowY 6% Y a: 7.2%-30.8%
Switched memory
CD271IgD2IgM2
NA NA 2.6% Y 1.6% Y 0.7% Y LowY 5% Y a: 6.5%-29.2%
Plasmablasts CD3811IgM2 NA NA <0.2% <0.2% <0.2% Low 1% a: 0.4%-3.6%
Activated CD38lowCD21low NA NA 3.8% 4.2% 6.9% LowY 4% a: 0.8%-7.7%
CD31 T cells 2100 3315 729 Y 2512 453 Y 470 Y 2970 a: 742-2750 / 56%-86%
CD41 582 1122 483 1039 189 Y 50 Y 510 a: 404-1612 / 33%-58%
CD81 624 1785 300 1140 272 440 2210 a: 220-1129 / 13%-39%
CD4/CD8 0.93 0.63 1.6 0.9 0.7 0.11 0.23 a: 0.6-2.8
NK 624 21% 466 507 105 70 680 a: 84-724 / 5%-26%
RTE
CD45RA1CD62L1CD311
NA NA 1.4% Y 1.2% Y 0.5% Y 1% Y 9% Y a: 14.4%-38.3%
CD41CD31 T cells
Naive (CD45RA1CCR71) NA NA 4.4% Y 4.4% Y 4.9% Y 1% Y 5% Y a: 20.5%-54.8%
TCM (CD45RA2CCR71) NA NA 28.0% 19.5% 47.2% 20% 40% a: 8.4%-32.8%
TEM (CD45RA2CCR72) NA NA 61.9% 56.8% 46.0% 77% 53% a: 19.9%-52.4%
TEMRA (CD45RA1CCR72) NA NA 5.7% 19.2% 2.0% 2% 3% a: 1.4%-17.0%
Treg FOXP31CD251 NA NA 3.8% 1.0% 4.2% NA NA HC: 2.0%-4.1%
Treg CD1272CD251 NA NA 4.7% 1.5% 4.3% NA NA HC: 3.2%-5.7%
Treg in vitro suppression NA NA NA NA Normal NA NA




NA NA 6.9% 2.3% 6.4% NA NA HC: 0.8%-1.4%
TH17: IL-17A in PMA-
stimulated cells
NA NA 2.4% 1.3% 4.6% NA NA HC: 0.2%-0.7%
TH1: IFN-g in PMA-
stimulated cells
NA NA 46.3% 42.3% 38.1% NA NA HC:16.2%-17.7%
CD81CD31 T cells
Naive (CD45RA1CCR71) NA NA 2.5 Y 1.6 Y 6.9 Y 1 Y 1 Y a: 18.8%-71.0%
TCM (CD45RA2CCR71) NA NA 0.8 0.4 16.3 1 2 a: 1.2%-7.3%
TEM (CD45RA2CCR72) NA NA 18.9 10.7 31.2 75 61 a: 14.6%-63.0%
TEMRA (CD45RA1CCR72) NA NA 87.8 39.0 45.5 24 36 a: 4.5%-33.7%













S-IgG 11.9 10.58 9.0 7.1 3.1Y 7.0 11.8 a: 6.77-15; 0-4 y: 2.3-13.1
S-IgA 0.96 2.34[ 1.94 0.29 0.66Y 0.58Y 1.24 a: 0.88-4.84; 0-4 y: 0.1-1.8
S-IgM 0.18Y 0.55Y 0.63 Y 1.04 <0.1Y 4.02 1.3 a: 0.88-4.84; 0-4 y: 0.2-1.9
S-IgE <5 <5 184 NA <2 NA 734 0-130
Vaccine responses
Pneumovax NA NA NA NA Absent Normal Normal
Tetanus NA NA Normal Normal Normal Normal Normal
Neutrophil function
Oxidative burst NA NA Normal Normal Normal NA NA
Complement
CH50, CH100 Normal Normal Normal Normal Normal NA NA
C3, C4 NA NA NA NA Normal Normal NA
Lymphocyte stimulation
responses
Pokeweed mitogens NA NA Weak Weak Very weak NA NA
PHA NA NA Weak Absent Weak Absent Very weak
Concanavalin A NA NA Very weak NA Very weak NA NA
(Continued)
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Reference valuesF1.P1 F1.P2 F2.P3 F3.P4 F4.P5 F5.P6 F5.P7
Anti-CD3 1 anti-CD28,
beads
NA NA Very weak Absent Very weak NA NA
Anti-CD3 1 anti-CD28,
soluble
NA NA Normal Absent Normal NA NA
a, Adults; NA, not applicable/available; RTE, recent thymic emigrant; TCR, T-cell receptor.
Absolute lymphocyte counts for F1.P2. were not available.
*The clinical significance of the observed 1-3 clonal expansions is not known, and may be reactive.
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amount of full-length DIAPH1 increased, suggesting that
DIAPH1 is relevant for proliferating lymphocytes (Fig 1, E; see
Fig E3 in this article’s Online Repository at www.jacionline.org).The novel DIAPH1:c.68411G>A disease variant is
enriched in the Finnish population
Comparison of variant frequency between populations in the
Genome Aggregation Database30 revealed that the c.68411G>A
variant is enriched in the Finnish population at an allele frequency
of 0.001125. In genotype data from approximately 11,400 indi-
viduals from Finnish population cohorts (FINRISK and TWIN
studies),31,32 the variant was present at a similar allele frequency.
To investigatewhether the c.68411G>Avariant had arisen from a
single mutational event, we carried out haplotype analysis for 20
unrelated, heterozygous, variant carriers in the cohort. The
analysis indicated that the c.68411G>A variant lied on a shared
ancestral haplotype with a median length of 8.8 Mb for shared
haplotype segments (Fig 1F; see Tables E4 and E5 in this article’s
Online Repository at www.jacionline.org). Average pairwise
identity-by-descent-sharing coefficients (PI-HAT) were 0.0038
for the whole cohort and 0.0067 for variant carriers, with values
ranging from 0 to 0.03 between distinct patient sample pairs
(see Table E6 in this article’s Online Repository at www.
jacionline.org), indicating greater than average genomic sharing
between some but not all carriers. Similarly, on a multidimen-
sional scaling plot, some of the variant carriers clustered together
whereas others exhibited comparatively low genomic sharing
(Fig 1, G). This suggests that the mutational event has not taken
place very recently. Using a previously published approach33
that uses the information on the haplotype arm lengths and
assuming a correlated genealogy, the age of themutation was esti-
mated at 17.9 generations (95% CI from 4.3 to 32.5 generations).Clinical characteristics of patients with SCBMS
Detailed clinical descriptions for each patient can be found in
this article’s Online Repository at www.jacionline.org. Shortly,
all studied patients had microcephaly, developmental delay,
epilepsy, and cortical blindness characteristic to the SCBMS
syndrome (Table I). Brain magnetic resonance imaging of
patients F1.P1, F1.P2, and F2.P3 demonstrated thin chiasm and
optic nerves, and T2-hyperintensewhitematter and cortical signal
abnormalities in bilateral occipital lobes (see Fig E4, A, in this
article’s Online Repository at www.jacionline.org). The clinical
presentation of F4.P5 and brain magnetic resonance imaging
have been previously described.34 In autopsy, neuropathological
examination of F1.P2 and immunohistochemical stainings
revealed several morphological abnormalities (Fig E4, B andC). In family 1, mitochondrial disease was suspected on the basis
of progressive brain atrophy, mildly elevated lactate/puryvate
ratio in blood, and increased number of mitochondria and mild
increase in fat in muscle biopsies. F2.P3, F5.P6, and F5.P7 also
presented with muscular hypotonia. Moreover, the patients
showed signs of immunodeficiency. F1.P1 and F1.P2 suffered
recurrent respiratory infections as well as persistent and extensive
Molluscum contagiosum lesions. In addition, F1.P1 had recurrent
oral herpes simplex virus and fungal infections throughout his
childhood. At 19 years, he had EBV viremia and subsequently
developed and succumbed to diffuse large B-cell lymphoma.
F1.P2 died of nonimmune causes (status epilepticus) at the age
of 6 years, but autopsy revealed a subclinical Hodgkin-type
lymphoma. In addition, patient F5.P6 died of EBV-positive
B-cell lymphoma at age 3 years (see Fig E5 in this article’s Online
Repository at www.jacionline.org). Patient F4.P5 suffered from
persistent vaccine strain Rubella skin infection and progressive
multifocal leukoencephalopathy positive for John Cunningham
virus. These clinical findings are consistent with poor T-cell
immunity.B-cell maturation defects
Complement activity, natural killer cell, and neutrophil counts
and oxidative burst were normal in all tested patients. However, 5
of the 7 patients were deficient with at least 1 major
immunoglobulin class. CD191 B cells were very low in 1 patient
(F5.P6), and immunophenotyping showed that proportions of
memory B cells, marginal zone CD271IgD1IgM1, and switched
memory CD271IgD2IgM2 B cells were low in the other 4
patients from whom PBMCs were available for analysis
(Table II). Proportions of transitional CD38hiIgMhi B cells in
turn were elevated.DIAPH1 is required for T-cell function
Lymphocyte differentials indicated abnormalities in the T-cell
compartment: CD31 T-cell counts were low or normal and
showed skewing of the CD4/CD8 ratio below 1. Patients
consistently showed defective T-cell maturation with low naive
CD41CD31 and CD81CD31 (CD45RA1CCR71) T-cell
populations and nearly absent CD45RA1CD62L1CD311 recent
thymic emigrant cells. Proportion of IFN-g and IL-17–positive
CD41 T-cell counts were high, indicating TH1 and TH17 activity,
respectively.
All patients from whom PBMCs were available for analysis
repeatedly showed a poor or absent lymphocyte proliferation
response to stimulation by concanavalin A, PHA, or anti-CD3/
CD28–coated beads (Table II; Fig 2, A and B). However,
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FIG 2. DIAPH1 is required for optimal T-cell responses. (A) PBL proliferation after stimulation by PHA was
estimated by phase-contrast imaging on ICAM-1–coated wells and (B) after stimulation by either anti-CD3/
CD28–coated beads (1:2 cell-bead ratio) or a mix of soluble anti-CD3/CD28 tetramers, IL-7 and IL-15 (both 3
ng/mL), by counting fold cell proliferation. C and D, Upregulation of activation markers CD69 and CD25 in
response to PHA or soluble antibodies or bead-bound anti-CD3/CD28 was assessed as a percentage of
CD31CD41 and CD31CD81 T cells by flow cytometry in patients F2.P3 and F3.P4 (Fig 2, C) and F4.P5
(Fig 2, D). E, Example of gating of DIAPH12 and DIAPH11 T cells in flow cytometry data after DIAPH1
knockout from healthy control PBMCs by CRISPR-Cas9. F, Transfected and mock-electroporated cells
were stimulated with either anti-CD3/CD28–coated beads or a soluble anti-CD3/CD28 tetramer with IL-7
and IL15, and upregulation of CD69 and CD25 was assessed by flow cytometry. Results were pooled
from duplicate samples generated with 2 different guide-pairs (N 5 4 per data point). HC, Healthy control;
ns, not significant. *P < .5, **P < .01, ***P < .001 (Student t test for 4 replicates assuming unequal variances).
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cytometric analysis after in vitro stimulation with PHA or
anti-CD3/CD28 beads, patient-derived T cells exhibited poor
upregulation of the activation markers CD69 and CD25,
especially in the CD81-cell subset (Fig 2, C and D). Stimulation
with soluble anti-CD3/CD28 resulted in a more variable result:
poor upregulation of both markers in F3.P4, otherwise normal
response except for weak CD25 upregulation in CD81 T cells
in F4.P5, and aWT-like response in F2.P3. Of note, F2.P3 showed
high spontaneous lymphocyte activation similar to what issometimes seen with chronic herpes simplex virus infection, but
test results for herpes simplex virus and EBV were negative.
To confirm reduced proliferation instead of increased apoptosis
of activated lymphocytes, the percentage of apoptotic cells was
estimated in 2 patients via an imaging-based AnnexinV-binding
assay. Neither patient showed increased activation-induced cell
death after stimulation by PHA or anti-CD3/CD28, although
baseline percentage of AnnexinV-positive cells was higher in the
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tubulin Phalloidin Hoechst Overlay
FIG 3. Analysis of T-cell adhesion, shape, and cytoskeletal organization. A-C, A total of 25,000 T cells were
plated on 8-well chamber slide coated with CD3 and CD28 antibodies, let attach for 1 hour, fixed, and stained
for F-actin. Imaging was done with Olympus FluoView FV1000 confocal microscope at 603. A, The number
of adhered cells counted from 6 replicate wells (;3-7 images/well) was lower for patient samples than
for healthy controls (P5 .001 for F2.P3/control; P5 .016 for F4.P5/control II). B, Cell circularity index (where
1 5 perfect circle) of 12 to 17 cells per study subject was measured using Fiji image analysis software. The
circularity index was higher in patient cells compared with control cells although only significantly so for
F2.P3 (P 5 .003). Error bars 5 SD. C, Representative microscopic fields of patient and control cells.
Blue 5 Hoechst (nucleus), green 5 Phalloidin (F-actin). D, T cells from 3 healthy donors and 2
patients (F2.P3 and F4.P5) were stained for a-tubulin to visualize the MTOC. The MTOC distance from
ICAM-1 1 anti-CD3–coated surface was measured in 3D in 300 cells/sample with Harmony 4.9 software,
and average distances were compared between patients and controls. Error bars 5 SD of the mean.
E, Representative microscopic fields of patient and control cells. Yellow 5 a-tubulin (MTOC), Red
(upper panel) 5 MitoTracker Deep Red (mitochondria), Red (lower panel) 5 Phalloidin AF647 (F-actin),
Blue 5 Hoechst (nucleus). Student t test: *P < .05, **P < .01, ***P < .001.
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replicates the SCBMS patient T-cell phenotype
To confirm that the T-cell activation defect was due to lack of
DIAPH1, we generatedDIAPH1 knockout cells from PBMCs of 2
healthy donors with the CRISPR-Cas9 method. Seven days after
electroporation, 20% to 40% of cells in each replicate sample
were negative for DIAPH1 protein (DIAPH12) as estimated by
flow cytometry (Fig 2, E). Samples were stimulated with
anti-CD3/CD28 beads or soluble antibody tetramers to assayupregulation of activation markers and proliferation. At 16 and
40 hours after stimulation, the percentage of cells positive for
CD69 and CD25 was markedly reduced in DIAPH12 cells
compared with DIAPH11 cells from the same donor (Fig 2, F).
In addition, after gating of CD69- or CD25-positive cells, median
fluorescence intensities of CD69 and CD25, respectively, were
significantly lower for DIAPH12 cells at most time points
(see Fig E7 in this article’s Online Repository at






































































Control C1 C2 C3 C4 C5 C6 C7
FIG 4. DIAPH1 affects CIV abundance. A, BN-PAGE for mitochondrial respiratory complexes indicated
selective deficiency of CIV in patient-derived immortalized fibroblasts. B, 2D-SDS-PAGE querying amount
of CIV (COX1 staining) and complex II (CII, SDHA staining) in patient and control fibroblasts. WT-DIAPH1
expression construct was introduced to patient and healthy control–derived immortalized fibroblasts,
and expression of several proteins and respiratory complexes was queried by western blotting in
(C) BN-PAGE for CIV and CII. D, SDS-PAGE for DIAPH1 and COX4 (CIV subunit) in individual
WT-DIAPH1-expression clones; GAPDH was used as a loading control. E, BN-PAGE for mitochondrial
respiratory complexes in individual clones. Bars represent mean band intensity and error bars SD from 3
separate sample preparations. Vertical black lines indicate the lanes were run on the same gel but were
noncontiguous. BN-PAGE, Blue Native Polyacrylamide Gel Electrophoresis; Relat., relative. P values were
calculated using Student t test: *P < .05, **P < .01, ***P < .001.
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patients lacking DIAPH1.T cells from patients with SCBMS exhibit impaired
cytoskeletal regulation
To investigate whether the mechanism of the T-cell activation
defect was related to the role of DIAPH1 in regulation of the
cytoskeleton, we studied cell morphology and adhesion, as well
as F-actin and a-tubulin organization by immunofluorescence
staining and microscopic imaging of T cells from patients and
healthy donors. When seeded on CD3/CD28 antibody–coated
surface, fewer patient than control cells were able to adhere
(Fig 3, A). In addition, patient cells seemed more circular than
control cells (Fig 3, B and C). Measurement of the MTOC
distance from surface in T cells seeded on ICAM-1 and CD3
antibody–coated wells indicated less efficient MTOC
reorientation to the immunologic synapse in patient-derived T
cells than control cells (Fig 3, D and E). These results suggest
altered cytoskeletal regulation in T cells lacking DIAPH1. No
consistent changes were found in amount or localization of
F-actin or mitochondria. We also tested chemotaxis of T cells
cultured for 10 days after stimulation with soluble CD3/CD28
antibodies, but found no difference in SDF1-a–driven chemotaxis
between patients (F2.P3 and F4.P5) and controls (see Fig E8 in
this article’s Online Repository at www.jacionline.org).DIAPH1 regulates mitochondrial respiration
through complex IV
In F1 patient–derived immortalized fibroblasts, we examined
the levels of mitochondrial respiratory chain complexes of the
mitochondrial oxidative phosphorylation system. Blue Native
Polyacrylamide Gel Electrophoresis analysis for complexes I to V
(CI-CV) revealed isolated deficiency of complex IV (CIV) (Fig 4,
A and B). To confirm the link between DIAPH1 and CIV by
complementation, we introduced a full-length WT-DIAPH1
expression construct into immortalized patient and control
fibroblasts by lentiviral gene transfer. Surprisingly, instead of
normalizing the amount of fully assembled CIV, DIAPH1
overexpression resulted in a dramatic decrease in CIV amount
in both control and patient total cell pools (Fig 4, C). In addition,
overexpression of DIAPH1 led to a decrease in actin levels (see
Fig E9 in this article’s Online Repository at www.jacionline.
org). On examination of individual patient fibroblast
overexpression clones, all clones showed higher DIAPH1
expression than WT fibroblasts (Fig 4, D). The expression of
COXIV (an individual subunit of complex IV) and the amount
of fully assembled CIV varied among separate clones expressing
WT-DIAPH1 (Fig 4,D andE). One of the clones (C4) had reached
the normal amount of fully assembled complex IV after the
complementation and thus the CIV defect was rescued by the
expression of WT-DIAPH1. Altogether this finding confirms
that the CIV deficiency detected in patient fibroblasts originally
was due to the lack of normal expression of DIAPH1.
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mitochondrial network in the immortalized fibroblasts using
antibodies against Tom20, a mitochondrial outer membrane
protein, and MT-CO1, a subunit of complex IV (see Fig E10 in
this article’s Online Repository at www.jacionline.org). Staining
for DIAPH1 showed a lack of DIAPH1 in patient fibroblasts and
clear overexpression of the protein after the complementation in
both patient and control fibroblasts. In WT cells, most of the
DIAPH1 protein localized to the cytoplasm and there was no
colocalization with mitochondrial markers. Interestingly, in
patient-derived fibroblasts overexpressing WT-DIAPH1,
MT-CO1 had a strong perinuclear localization, but based on
staining for Tom20, the overall distribution of the mitochondrial
network was not changed.Mitochondrial function in T cells lacking DIAPH1
Becausewe had detected reduced CIV in patient fibroblasts, we
hypothesized that the immunodeficiency in patients with SCBMS
could also be linked to altered mitochondrial function. Hence, we
analyzed mitochondrial membrane potential (MMP) of patient-
and control-derived lymphocytes by treating the cells with
tetramethylrhodamine ethyl ester, a dye that accumulates in
mitochondria, based on their negative MMP. Although results
from CD41 cells were comparable between patients and controls,
the tetramethylrhodamine ethyl ester signal-profile differed
markedly between control and patient CD81 T cells (see Fig
E11, A, in this article’s Online Repository at www.jacionline.
org). In control CD31CD81 cells, 2 populations with different
peak fluorescence intensities were detected, whereas patient
(F2.P3 and F3.P4) CD31CD81 cells showed only 1 population
with an MMP signal localizing between those of the populations
detected in controls.
To investigate whether there were differences in mitochondrial
mass between samples, lymphocytes were stained with
nonylacridine orange, a reagent that enters mitochondria
independently of MMP. Patients, especially F2.P3, had a higher
number of lymphocytes with a slightly lower mitochondrial mass
(Fig E11, B).
We also assayed upregulation of cellular and mitochondrial
calcium after activation with anti-CD3/CD28 beads in PBLs
loaded with the fluorescent Ca21 indicators Fluo-4 AM and
Rhod-2 AM, respectively. To account for differences in reagent
loading between samples, we analyzed signal intensity fold
induction in response to stimulation. Patient PBLs exhibited a
significantly weaker upregulation of mitochondrial Ca21 in
response to stimulation than controls (Fig E11, C).DISCUSSION
In 5 patients from 4 unrelated Finnish pedigrees, we found
homozygosity for a rare DIAPH1 splice variant (c.68411G>A)
that leads to SCBMS via loss of the DIAPH1 protein. This variant
is enriched in the Finnish population at an allele frequency of
roughly 0.1%, and haplotype analysis implied a common ances-
tral origin for the variant. The DIAPH1 c.68411G>A variant is
responsible for all cases of SCBMS identified in Finland thus
far and is, to our knowledge, the first disease-causing variant in
DIAPH1 to have population-level impact. In addition, 2
additional patients originating fromOmanwith no known relationto previously published patients were found homozygous for the
DIAPH1:c.2769delT;p.F923fs variant.22
The SCBMS syndrome seems to be readily identifiable by the
hallmark symptoms of microcephaly, early-onset refractory
epileptic seizures, cortical blindness, and intellectual disability
exhibited by all patients.12,22 In addition, all patients reported
here had findings supporting immunodeficiency and some had
signs of mitochondrial dysfunction. Clinically, the patients
suffered from infection susceptibility and B-cell lymphomas,
both of which are common occurrences in immunodeficient
patients.35,36 Immunologic investigations revealed that the
patients were severely deficient in naive T-cell populations.
This implies that similar problems in T-cell egression from the
thymus take place in patients with SCBMS as have been
demonstrated in DIAPH12/2 mice.14 Moreover, upregulation of
activation markers and proliferation of patient T cells in response
to stimulation by mitogens or anti-CD3/CD28 was markedly
reduced similarly towhat has been seen in theDIAPH12/2mouse
model.9,14 This defect was reproduced by CRISPR-Cas9
knockout of DIAPH1 in healthy donor PBMCs, indicating that
depressed T-cell immunity in patients is directly caused by lack
ofDIAPH1. Variation in the severity of the T-cell activation defect
between patients and between healthy donor cells subjected to
CRISPR-Cas9 knockdown of DIAPH1 suggests modifying
genetic factors.
While investigating the mechanism behind the functional
T-cell defect, we found that patient-derived T cells exhibited
impaired adhesion and inefficient MTOC translocation to the
immunologic synapse. This cytoskeletal reorganization is
essential for T-cell function.37 An MTOC repolarization defect
has also been demonstrated previously in a Jurkat DIAPH1
knockdown model.15 Considering these and previously published
results on functions of DIAPH1 in actin nucleation and
microtubule organization, immune presentations in patients
with SCBMS are not surprising, because mutations in several
genes involved in regulation of the cytoskeleton cause primary
immunodeficiency.38
DIAPH1 has previously been demonstrated to regulate
mitochondrial motility and distribution.6,7 However, the
mitochondrial network in SCBMS patient–derived fibroblasts
seemed normal based on Tom20 staining. Instead, these cells
showed deficiency of CIV, an integral part of mitochondrial
respiration and regulator of mitochondrial oxidative
phosphorylation.39 CIV deficiency is one of the most common
mitochondrial diseases and can be caused by mutations in several
genes encoding for CIV subunits or assembly factors.40 Typical
pathology is somewhat dependent on the affected genes and
tissues, but invariably includes encephalopathy, which is also a
significant symptom of SCBMS. In patient T cells, we found
changes in mitochondrial membrane potential and calcium.
Changes in MMP in patient’s CD81 cells could reflect alterations
in CD81 naive to experienced cell ratio, mitochondrial energy
production, or both.41,42 Patient PBL also showed attenuated
elevation of mitochondrial calcium in response to T-cell receptor
engagement. This could be secondary to impairment of MTOC
localization, because activation of calcium influx at the immuno-
logic synapse is dependent on cytoskeletal reorganization.43
Because, however, mitochondrial localization and bioenergetics
are a major regulator of immune cell function,44-48 immunome-
tabolism in patients with SCMBS would be an interesting target
for future investigations.
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Our observations suggest that biallelic loss of DIAPH1
negatively affects T-cell function and can lead to combined
immunodeficiency. Hence, clinicians treating patients with
SCBMS should be aware of a heightened risk for developing
severe or recurrent infections and lymphoma. Furthermore, our
findings indicate that the pathogenetic mechanism of SCBMS
may be linked to impaired regulation of cytoskeletal organization
and to mitochondrial dysfunction. However, the exact
mechanistic links between DIAPH1 and the cytoskeleton,
mitochondrial function, CIV, and T-cell responses warrant further
investigations.
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Key messages
d Clinicians treating patients with SCBMS should be aware
of a higher risk for persistent infections and lymphoma.
d Loss of DIAPH1 can result in aberrant B- and T-cell
maturation and reduction in T-cell functionality due to
defects in cytoskeletal organization.
d Mitochondrial dysfunction may underlie aspects of
DIAPH1-related disease.REFERENCES
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